Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Prepaid Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Prepaid Assets for 16 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets changed N/A to $17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.0 million, a N/A change, with the full-year FY2025 number at $17.0 million, changed N/A from a year prior.
  • Prepaid Assets was $17.0 million for Q4 2025 at Cytokinetics, up from $13.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $20.0 million in Q2 2025 to a low of $3.0 million in Q1 2021.
  • A 5-year average of $13.8 million and a median of $14.3 million in 2022 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 423.44% in 2021, then crashed 66.13% in 2024.
  • Cytokinetics' Prepaid Assets stood at $12.2 million in 2021, then increased by 2.02% to $12.5 million in 2022, then fell by 4.16% to $11.9 million in 2023, then plummeted by 44.2% to $6.7 million in 2024, then surged by 154.91% to $17.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Prepaid Assets are $17.0 million (Q4 2025), $13.0 million (Q3 2025), and $20.0 million (Q2 2025).